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Over four decades ago, in vitro experiments showed that tau protein interacts with
and stabilizes microtubules in a phosphorylation-dependent manner. This observation
fueled the widespread hypotheses that these properties extend to living neurons and
that reduced stability of microtubules represents a major disease-driving event induced
by pathological forms of tau in Alzheimer’s disease and other tauopathies. Accordingly,
most research efforts to date have addressed this protein as a substrate, focusing
on evaluating how specific mutations, phosphorylation, and other post-translational
modifications impact its microtubule-binding and stabilizing properties. In contrast,
fewer efforts were made to illuminate potential mechanisms linking physiological and
disease-related forms of tau to the normal and pathological regulation of kinases and
phosphatases. Here, we discuss published work indicating that, through interactions
with various kinases and phosphatases, tau may normally act as a scaffolding protein to
regulate phosphorylation-based signaling pathways. Expanding on this concept, we also
review experimental evidence linking disease-related tau species to the misregulation
of these pathways. Collectively, the available evidence supports the participation
of tau in multiple cellular processes sustaining neuronal and glial function through
various mechanisms involving the scaffolding and regulation of selected kinases and
phosphatases at discrete subcellular compartments. The notion that the repertoire
of tau functions includes a role as a signaling hub should widen our interpretation
of experimental results and increase our understanding of tau biology in normal and
disease conditions.
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INTRODUCTION
In 1975, the microtubule (MT)-associated protein tau was identified by the Kirschner laboratory
as a protein that co-purified with tubulin and that significantly enhanced MT assembly in vitro
(Weingarten et al., 1975; Witman et al., 1976; Cleveland et al., 1977a,b). These findings, together
with the widespread expression of tau in the nervous system and its presence in axons, led to
the presumption that tau was needed to stabilize microtubules in the axon, which has continued
to be the most common description of tau function. Curiously, the generation of tau-null
mice fell short of broadly changing this initial perception, despite their modest phenotype with
advancing age and largely normal appearance of their nervous system (Harada et al., 1994;
Dawson et al., 2001).
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Several independent reports also showed that tau is the main
constituent of paired helical filaments, a major histopathological
hallmark of neurons affected in a group of neurodegenerative
disorders termed tauopathies, which includes Alzheimer’s
disease (AD; Grundke-Iqbal et al., 1986; Ihara, 1986; Wood et al.,
1986; Kosik et al., 1988). In the mid-90s, strong genetic evidence
linking mutations in the MAPT gene to inheritable forms of
tauopathies indicated that altered tau function contributes to the
pathogenesis of these diseases (Spillantini and Goedert, 1998).
Also, amyloid-β neurotoxicity was reported to depend, at least
in part, on the presence of tau protein (Rapoport et al., 2002).
Thus, earlier work suggested a role for tau in stabilizing the
MT cytoskeleton, further implicating this protein as an active
contributor to neurodegenerative disease pathogenesis.
Concurrently, a significant body of experimental evidence
gradually emerged suggesting that the repertoire of physiological
tau functions might extend well beyond the regulation of
MT stability. For example, early immunohistochemical studies
documented tau localization at the leading growth cone of
developing neurites, a compartment largely devoid of stable MTs
(DiTella et al., 1994; Brandt et al., 1995; Black et al., 1996; Liu
et al., 1999). Also, tau is localized within dendrites and somata of
neuronal cells, and within compartments featuring scarce MTs,
such as the nucleus and the subcortical cytoskeleton immediately
adjacent to the inner plasma membrane (Papasozomenos and
Binder, 1987; Loomis et al., 1990; Brandt et al., 1995). Although
these observations strongly implied tau functions unrelated to
MT stabilization, research efforts focused on unveiling such roles
have remained relatively limited. Illuminating compartment-
specific functions of tau would significantly advance our
knowledge of its normal physiology and provide critical clues on
the pathobiological roles played by this protein.
Scaffold proteins are important regulators of many
intracellular signaling pathways. They often interact with various
signaling proteins, coordinating their activities and localizing
them to discrete cellular compartments or structures (Lester
and Scott, 1997; Shaw and Filbert, 2009; Buday and Tompa,
2010). Interestingly, tau was reported to interact with many
signaling proteins serving a wide variety of cellular functions
(Morris et al., 2011; Sinsky et al., 2020). Notably, among tau
interactors are a wide variety of kinases and phosphatases
including protein phosphatase 1 (PP1), protein phosphatase 2A
(PP2A), glycogen synthase kinase 3β (GSK3β), cyclin-dependent
protein kinase 5 (CDK5), src-family kinases (cSrc, Fgr, Fyn, and
Lck), as well as other proteins with established roles in signaling
pathways including growth factor receptor-bound protein 2
(Grb2), p85α, and PLCγ (Liao et al., 1998; Sontag et al., 1999,
2012; Sun et al., 2002; Morris et al., 2011). Independently, other
microtubule-associated proteins were found to interact with
protein kinases. Among those, MAP2 interacts with protein
kinase A (PKA) and acts as a PKA-anchoring protein (AKAP)
that localizes this kinase in dendrites (Carnegie and Scott, 2003;
Zhong et al., 2009).
Scaffold proteins commonly exhibit a remarkable degree of
conformational flexibility, a feature that facilitates their dynamic
interaction with multiple binding partners (Gunasekaran et al.,
2003; Tompa and Fersht, 2009). Such flexibility represents
another characteristic of tau documented by extensive structural
and biophysical studies (Mandelkow and Mandelkow, 2012;
Sabbagh and Dickey, 2016; Stern et al., 2017). Indeed,
intrinsically disordered proteins, including tau, are known for
their unique structural plasticity, conformational adaptability,
and binding promiscuity enabling their involvement in diverse
signaling roles (Uversky, 2015; Brandt et al., 2020). Interestingly,
there is a clear evolutionary increase in disorder within the
amino-terminal region of tau that likely enabled the development
of novel protein-protein interactions (Trushina et al., 2019). It
is noteworthy that, despite being categorized as an intrinsically
disordered protein, tau is known to adopt specific folded
conformations as a soluble protein (e.g., global hairpin folding;
Jeganathan et al., 2006) and in the context of pathology (as
identified by conformation-specific antibodies such as Alz50 or
MC1; Wolozin et al., 1986; Carmel et al., 1996; Jicha et al., 1997,
1999). Some studies estimated the majority of tau is bound to
MTs at any given moment, despite its dynamic interaction with
MTs (∼40 ms residence time in vitro). Such dynamics likely
impact tau’s availability to interact with kinases and phosphatases
on and off the MT surface (Weissmann et al., 2009; Janning
et al., 2014). Based on its widespread subcellular distribution,
diverse interactome and highly dynamic structural properties,
tau could be considered a scaffold protein or ‘‘signaling hub’’
for the regulation of phosphorylation-based pathways in discrete
subcellular compartments, as previously suggested (Lee et al.,
1998; Morris et al., 2011; Kanaan et al., 2012; Götz et al., 2013;
Sotiropoulos et al., 2017).
The goal of this review is to present an overview of
published work supporting the role of tau in numerous
cellular processes through interactions with and/or regulation of
selected kinases and phosphatases. This overview includes the
description of a PP1-GSK3β pathway by which tau regulates
the transport of vesicles and other cellular organelles in axons.
We also describe evidence supporting the role of tau on the
regulation of Fyn kinase at post-synaptic compartments and
oligodendrocyte processes, which impacts synaptic function and
myelination, respectively. We discuss the potential roles of
tau on the modulation of signaling pathways in nuclear and
synaptic compartments.We succinctly review emerging evidence
suggesting a role of tau on the modulation of phosphorylation-
based pathways elicited by insulin and neurotrophic factors.
Finally, based on strong genetic and experimental evidence
linking pathological forms of tau to tauopathies, we examine
evidence demonstrating deregulation of these pathways by
pathogenic forms of tau.
TAU REGULATION OF SIGNALING
PATHWAYS IN AXONS
The movement of membrane-bound organelles (MBOs) along
axons, a cellular process referred to as fast axonal transport
(FAT), is critical for appropriate maintenance of neuronal
connectivity and survival (Black, 2016). The correct functionality
of specialized axonal subcompartments, including nodes of
Ranvier and pre-synaptic terminals, critically depends on the
sustained supply of MBOs moving via anterograde FAT (aFAT;
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from the neuronal soma towards the cell periphery). Conversely,
neuronal survival and homeostasis depend on retrograde
FAT (rFAT) of specialized MBOs bearing neurotrophins and
degraded materials from peripheral compartments towards the
neuronal soma. In the mature brain, aFAT and rFAT are
mainly driven by the multi-subunit motor proteins kinesin-1
(conventional kinesin) and cytoplasmic dynein, respectively.
Both directions of FAT are regulated, in part, by signaling
pathways controlling phosphorylation of these microtubule-
based motors (Gibbs et al., 2015; Brady and Morfini, 2017).
Highlighting the critical importance of FAT regulation to
neuronal function, genetic and experimental evidence has linked
deficits in FAT, synaptic dysfunction, and axonal pathology
to numerous neurodegenerative diseases, including tauopathies
(Morfini et al., 2009; Kanaan et al., 2013; Kneynsberg et al., 2017).
A PP1-GSK3β pathway was previously defined that selectively
regulates kinesin-1-based aFAT (Morfini et al., 2004). This
pathway involved PP1 activation, resulting in dephosphorylation
and activation of GSK3β, GSK3β-mediated phosphorylation of
kinesin-1 light chain subunits, and detachment of this motor
protein from its transported MBO cargoes (Ratner et al.,
1998; Morfini et al., 2002, 2004; Figure 1, lower panel). Tau’s
role in regulating this pathway was identified by experiments
in isolated squid axoplasm, a plasma membrane-free ex vivo
preparation uniquely suited for the study of FAT mechanisms
(Gibbs et al., 2015; Song et al., 2016). Perfusion of squid
axoplasm with physiological levels of recombinant human
wild-type tau monomers did not affect aFAT or rFAT. In
contrast, perfusion of axoplasm with disease-related forms of
tau, including mutant and aggregated forms, selectively inhibited
aFAT in a manner dependent on PP1 and GSK3β activities
(LaPointe et al., 2009; Kanaan et al., 2011, 2012; Cox et al.,
2016). Providing a mechanistic basis for these results, deletion
experiments mapped a specific motif in the extreme N-terminus
of tau, termed the Phosphatase Activating Domain (PAD),
which was necessary and sufficient to activate the PP1-GSK3β
pathway in axons (Kanaan et al., 2011, 2012). Specifically,
aggregates composed of tau in which PAD was deleted did not
inhibit aFAT, whereas perfusion with a synthetic PAD peptide
(amino acids 2-18) sufficed to inhibit aFAT in the isolated
axoplasm preparation (Kanaan et al., 2011). The observation
that wild-type, soluble monomeric tau did not affect FAT
despite featuring the PAD was consistent with studies showing
that soluble tau monomers adopt a globally folded ‘‘paperclip’’
conformation, in which the C-terminus interacts with the
MTBR, and the N-terminus interacts with the C-terminus
FIGURE 1 | Tau regulates anterograde fast axonal transport through a PP1-GSK3β pathway. Lower panel: Exposure of a phosphatase activating domain (PAD,
red domain) located at the N-terminus of tau causes activation of protein phosphatase 1 (PP1, in purple). Active PP1 (labeled by red asterisks) dephosphorylates and
activates glycogen synthase kinase 3β (GSK3β). Active GSK3β (labeled by red asterisks) phosphorylates light chain subunits of kinesin-1, an event that promotes the
release of membrane-bound organelle (MBO) cargoes transported by this major motor protein. Spatially discrete post-translational modifications in tau that either
promote (i.e., phosphorylation events in the proline-rich region) or prevent (i.e., N-terminal phosphorylation) PAD exposure may thus allow the localized delivery of
selected MBOs at functionally distinct axonal subdomains, such as en passant pre-synaptic terminals or nodes of Ranvier under normal physiological conditions.
Although depicted bound to microtubules (MT), tau’s dynamic interaction with MTs in normal conditions likely provides opportunities for tau to interact with PP1
(and/or other enzymes) on or off the MT surface. Upper panel: By extension, aberrant PAD exposure associated pathological forms of tau such as
aggregates/oligomers (oTau), mutant tau, and selected pathological post-translational modifications (e.g., phosphorylation, pTau), may disrupt homeostatic
maintenance of this process.
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(Jeganathan et al., 2006). Thus, folding of tau into the paperclip
or paperclip-like conformations likely reduces exposure and
accessibility of PAD in the soluble monomeric state. In support,
monomeric tau lacking amino acids 144-273, a region that
confers flexibility necessary for the N-terminus to fold into
the paperclip conformation, inhibited aFAT when perfused in
the isolated squid axoplasm preparation (Kanaan et al., 2011).
Relevant to disease pathogenesis, truncation of amino acids
144-273 in tau is caused by a mutation in MAPT associated
with an inherited tauopathy (Rovelet-Lecrux et al., 2009).
Collectively, the findings above revealed a mechanism where
various pathological modifications, including selectedmutations,
truncations, and aggregation, induced conformational changes
in tau that promoted PAD exposure, activation of a PP1-GSK3β
pathway, and inhibition of aFAT (Figure 1, upper panel).
In addition to mutations and aggregation, some
phosphorylation events in tau were also found to promote
PAD exposure, activation of the PP1-GSK3β pathway, and
FAT inhibition. For example, the paperclip conformation is
disrupted in tau monomers featuring pseudophosphorylation
of three residues within the AT8 antibody epitope (i.e., S199,
S202, and T205; pAT8-Tau), causing aberrant exposure of
the N-terminus (Jeganathan et al., 2006; Kanaan et al., 2011).
As expected, perfusion of squid axoplasm with pAT8-Tau
monomers inhibited aFAT, an effect blocked by both PP1 and
GSK3β inhibitors (Kanaan et al., 2011). In addition, aggregates
composed of tau pseudophosphorylated at S422, a modification
found in pre-tangle neurons affected early in AD, also inhibited
both aFAT and rFAT when perfused in isolated axoplasm,
but a potential involvement of PAD on these effects has not
yet been evaluated (Tiernan et al., 2016). The highly dynamic
conformational flexibility of tau, differentially impacted by
phosphorylation of specific residues, might confer upon this
protein its ability to work as a signaling hub and activate and/or
modulate different signaling pathways (Smith et al., 2006; Kang
et al., 2020). Collectively, these and other studies suggest a
complex relationship between specific phosphorylation events
in tau and their net impact on tau conformation, as well as the
potential co-existence of additional biologically active domains
in tau that, like PAD, may promote activation of other signaling
pathways (Morris et al., 2020).
The ability of PAD to recruit and activate a PP1-GSK3β
pathway close to microtubules bears important implications
for our understanding of axon-specific functions of tau in
normal and disease states (Figure 1). For example, spatially
discrete phosphorylation events in tau that promote PAD
exposure may facilitate the delivery of selected MBOs to their
correct destinations (i.e., MBOs containing synaptic vesicle
precursors to pre-synaptic terminals, or MBOs containing
sodium channels at nodes of Ranvier; Morfini et al., 2001, 2016).
Interestingly, phosphorylation of Y18 within PAD prevented
the inhibitory effect of pathological tau species on aFAT
(Kanaan et al., 2012), suggesting that phosphorylation of the
Y18 residue by non-receptor tyrosine kinases might act as
a negative feedback mechanism to prevent or downregulate
PAD-dependent activation of the PP1-GSK3β pathway (Lee
et al., 2004; Lebouvier et al., 2008; Lee and Leugers, 2012).
Truncation of tau’s N-terminal region containing PAD by
caspases or other proteases may represent an irreversible version
of another negative feedback mechanism (Horowitz et al.,
2004; Sengupta et al., 2006). Finally, the intriguing observation
that tau phosphorylation at the Tau1 epitope (aa 192-204) is
significantly lower in axons than in the soma and dendrites
might relate to modulatory effects of this modification on global
tau conformation, which in turn would promote or prevent
activation of selected signaling pathways at discrete subcellular
compartments (Papasozomenos and Binder, 1987; Mandell and
Banker, 1995).
PAD’s contribution to neuronal pathology in the context
of tauopathies is supported by immunochemical studies using
the monoclonal antibodies tau N-terminal 1 and 2 (TNT1 and
TNT2). These antibodies selectively recognize an epitope within
PAD that is exposed in a conformation-dependent manner
(Kanaan et al., 2011; Combs et al., 2016; Cox et al., 2016).
Neurons featuring pre-tangle tau inclusions are immunoreactive
to TNT antibodies across all Braak stages with relatively little
reactivity in control cases and substantial reactivity in AD brains
(Kanaan et al., 2011; Combs et al., 2016). TNT1/2 antibodies
also robustly label tau inclusions in several non-AD tauopathies
including progressive supranuclear palsy (PSP), corticobasal
degeneration (CBD), Pick’s disease, and chronic traumatic
encephalopathy (CTE; Kanaan et al., 2011, 2012; Combs et al.,
2016; Cox et al., 2016; Tiernan et al., 2016; Combs and Kanaan,
2017). Moreover, pathological forms of tau known to inhibit FAT
including oligomers, AT8 phospho-tau, and tau phosphorylated
at Ser422 are all recognized by TNT1 and TNT2 antibodies in
the context of human tauopathies (Kanaan et al., 2011, 2012,
2016; Patterson et al., 2011; Combs et al., 2016; Cox et al.,
2016; Tiernan et al., 2016; Morris et al., 2020). Overall, this
body of work strongly supports a mechanism linking several
specific pathological tau species to aberrant PAD exposure,
abnormal activation of a PP1-GSKβ pathway, and deficits in
FAT. Potential pathological consequences of tau-induced FAT
deficits may include impaired delivery of synaptic vesicles and/or
mitochondria to pre-synaptic compartments, which would
promote synaptic dysfunction and degeneration (Kneynsberg
et al., 2017; Pérez et al., 2018).
TAU MODULATION OF SIGNALING
PATHWAYS CONTROLLING SYNAPTIC
FUNCTION
Long-term, activity-dependent strengthening or weakening of
synapses are referred to as long-term potentiation (LTP) or
long-term depression (LTD), respectively (Lüscher andMalenka,
2012). The regulation of both LTP and LTD involves the
coordinated modulation of several neurotransmitter receptors
and their downstream signaling pathways. N-methyl-D-aspartate
receptors (NMDARs) are major mediators of LTP, although
some forms of LTP are NMDAR-independent and can
involve metabotropic receptors, kainate receptors, and α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic receptors (AMPARs;
Bliss et al., 2018). One mechanism that underlies the sustained
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enhanced synaptic response in LTP is the insertion of α-amino
AMPARs into the synaptic membrane (Bliss et al., 2018).
Conversely, AMPAR endocytosis is a mechanism contributing
to LTD (Lüscher and Malenka, 2012). Accumulating evidence
suggests that, by regulating the activity of specific signaling
proteins involved in these processes, tau may impact synaptic
function in health and disease states.
Under normal conditions, tau undergoes activity-dependent
translocation to excitatory post-synapses (Frandemiche et al.,
2014), a location where tau interacts with Fyn kinase and
other post-synaptic proteins, including PSD-95 and NMDARs
(Ittner et al., 2010). Analysis of tau knockout mouse models
suggested the involvement of tau in the regulation of LTP,
LTD, or potentially both (Ahmed et al., 2014; Kimura et al.,
2014; Regan et al., 2015). Interestingly, Regan et al. (2015)
showed that hippocampal LTD requires phosphorylation of tau
at S396 (a residue within the PHF-1 epitope; Kimura et al.,
2014). While these studies provide evidence that tau modulates
synaptic function, the precise mechanisms and/or requirement
of tau for LTP and LTD requires further investigation. In
the context of disease, other studies documented the effects
of pathological tau species on synaptic function (Tracy and
Gan, 2018; Hanger et al., 2019; Hill et al., 2020). Indeed,
oligomeric tau, mutant forms of tau associated with inherited
tauopathies, abnormally phosphorylated tau species, acetylated
tau, and caspase-cleaved tau were shown to impair LTP
and/or LTD function, promoting abnormal AMPAR trafficking
through various mechanisms (Yoshiyama et al., 2007; Hoover
et al., 2010; Warmus et al., 2014; Min et al., 2015; Fá et al.,
2016; Tracy et al., 2016; Zhao et al., 2016; Puzzo et al.,
2017; Ondrejcak et al., 2018). Below, we present a succinct
discussion of mechanisms linking tau to the regulation of
signaling pathways sustaining the functionality of pre- and
post-synaptic compartments.
Several studies indicated that neural network excitability
is promoted by tau overexpression and counteracted by tau
reduction (Roberson et al., 2007; Miyamoto et al., 2017).
These effects were linked to alterations in the subcellular
localization and activity of Fyn, a member of the Src family of
non-receptor tyrosine kinases highly enriched in brain tissue.
Mice overexpressing Fyn showed NMDAR overactivation and
excitotoxicity, highlighting a role for this kinase on synaptic
function (Ittner et al., 2010; Xia et al., 2015). The projection
domain of tau contains seven PXXP motifs, two of which can
directly interact with the SH3 domain of Fyn (Umemori et al.,
1992; Lee et al., 1998). Specifically, tau-Fyn interaction depends
on prolines 213, 216, and 219 within the fifth and sixth PXXP
motifs (Lau et al., 2016), although isoform-specific differences
may exist (Bhaskar et al., 2005). Known tau modifications,
such as phosphorylation in the N-terminal half of the protein
(Bhaskar et al., 2005; Reynolds et al., 2008) and pathological
aggregation (Fitzpatrick et al., 2017; Goedert and Spillantini,
2019), may alter tau conformation in the proline-rich region
and block Fyn binding domains. Tau is not only a substrate
of Fyn (Lee et al., 2004; Bhaskar et al., 2005), but also
increases auto-phosphorylation and activation of this kinase
(Sharma et al., 2007).
Several lines of evidence support the tau-based localization
of Fyn to the postsynaptic compartment. For example, reduced
levels of Fyn in post-synapses were observed in tau knockout
mice (Ittner et al., 2010). Also, a recent study used single-
molecule tracking to show that tau knockdown increased the
mobility of Fyn in dendritic shafts (as opposed to spines), an
effect rescued by tau expression (Padmanabhan et al., 2019).
Tau-mediated localization of Fyn to post-synapses facilitated
Fyn-mediated phosphorylation of the NMDAR subunit 2b at
tyrosine 1472 (Nakazawa et al., 2001; Ittner et al., 2010). This
phosphorylation event promotes stabilization of NMDARs by
facilitating their interaction with the scaffolding protein PSD-95
(Grant et al., 1992; Suzuki and Okumura-Noji, 1995; Nakazawa
et al., 2001; Roche et al., 2001; Rong et al., 2001). Conversely,
reduced localization of Fyn to the post-synapse negatively
impacted the stability of the NMDAR-PSD-95 complexes (Ittner
et al., 2010). Collectively, these studies demonstrate that tau acts
as a scaffold protein for Fyn in the post-synaptic compartment
where it participates in NMDAR-mediated synaptic functions by
modulating Fyn localization and/or activity (Figure 2).
Pathological forms of tau promote abnormalities in the
Fyn-dependent control of synaptic function through a variety
of mechanisms. Some tau mutants associated with inherited
tauopathies displayed increased interaction with Fyn (Bhaskar
et al., 2005), and other reports documented abnormalities in
Fyn localization in mouse models of inheritable tauopathies.
For example, recent characterization of Fyn nanoclustering in
mouse hippocampal dendritic spines showed that P301L mutant
tau trapped Fyn in the spines (Padmanabhan et al., 2019),
a finding consistent with prior reports (Hoover et al., 2010;
Ittner et al., 2010; Xia et al., 2015), and a role of tau as a
scaffolding protein. Also, Hoover and colleagues documented
increased localization of P301L tau in dendritic spines of rat
cultured neurons compared to wild-type tau, and this finding
was confirmed in living neurons of transgenic mice expressing
mutant P301L tau (Tg4510 line; Hoover et al., 2010). Using
overexpression experiments in cultured mouse hippocampal
neurons, Xia et al. (2015) reported 5-fold higher levels of spine
localization for P301L tau, compared to wild-type tau. Both
groups also showed that phosphorylation of tau at specific sites
influenced its targeting to dendritic spines (Hoover et al., 2010;
Xia et al., 2015). Together, these studies suggest that mutations
and specific phosphorylation events may affect tau’s ability to
localize to post-synapses and/or bind and activate Fyn, an event
that might contribute to the synaptic dysfunction phenotype
observed in tauopathies.
In recent years, additional experimental evidence indicated
a potential role for tau in pre-synaptic function through
PP1 regulation. For example, injection of wild-type tau in
pre-synaptic terminals of the squid giant synapse increased
Ca2+ release and reduced neurotransmitter release. This effect
was associated with rapid phosphorylation of tau at the
AT8 epitope (Moreno et al., 2016), an event that promotes
increased exposure of PAD (Kanaan et al., 2011). Accordingly,
co-injection of wild-type tau with TNT1 antibody prevented
its toxic effect on synaptic transmission (Moreno et al.,
2016). Independently, other studies revealed increased levels
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FIGURE 2 | Tau regulates several signaling synaptic pathways. Upper panel: At the pre-synaptic compartment, tau undergoes phosphorylation at the AT8 epitope
(pTau). This event promotes PAD exposure, which in turn increases Ca2+ release from intracellular stores and reduces neurotransmitter release in an IP3-dependent
manner, which might involve PP1 and/or GSK3 (indicated by a red question mark). Also, pathological forms of tau reportedly restrict vesicle mobility through scaffold
interactions with the vesicular protein synaptogyrin-3 and F-actin. Lower panel: Tau localizes Fyn to the post-synapse allowing Fyn to phosphorylate NMDAR2b at
Y1472, which leads to NMDAR stabilization via interaction with PSD-95. Pathological forms of tau including aggregated/oligomeric tau (oTau), specific
phosphorylated forms of tau (pTau), or mutant tau (muTau) can affect tau-Fyn binding, ultimately leading to aberrant synaptic activity by promoting increased trapping
of Fyn in dendritic spines.
of phosphorylated tau associated with synaptic vesicles in AD
tissue, and mutant forms of tau (e.g., P301L, P301S, R406W, or
V337M tau) interfered with pre-synaptic function in multiple
models of tauopathy (Zhou et al., 2017; McInnes et al.,
2018). Mechanistically, these effects were linked to abnormal
scaffolding behavior of tau, which restricted vesicle mobility
through interactions with synaptogyrin-3 and actin (Zhou et al.,
2017; McInnes et al., 2018). Collectively, these findings suggest
that tau regulates the functionality of pre- and post-synaptic
compartments through the modulation and/or localization of
kinases and phosphatases and that pathological forms of tau
may alter such regulation through a variety of mechanisms
(Figure 2).
TAU REGULATION OF SIGNALING
PATHWAYS IN THE NUCLEUS
By regulating the activity of PP1 and associated downstream
signaling cascades, tau might regulate cellular processes in
compartments beyond axons and synapses. In support, both
tau and PP1 localize to the nucleus and soma (Rebelo et al.,
2015; Maina et al., 2016). PP1 is known to modulate multiple
signaling pathways (Rebelo et al., 2015), including a Wnt/β-
catenin pathway that promotes cell survival (Chen et al., 2001;
Voskas et al., 2010). This pathway involves phosphorylation-
dependent β-catenin degradation in the cytoplasm by a
β-catenin destruction complex composed of the proteins
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[GSK3β, casein kinase-I (CK-I), and adenomatous polyposis
coli (APC)] assembled by the scaffolding protein axin-I.
Disruption of this protein complex promotes the accumulation of
dephosphorylated β-catenin in the cytoplasm and its subsequent
translocation into the nucleus. Within the nucleus, β-catenin
associates with T-cell factor/lymphoid enhancer-binding factor
(TCF/LEF) DNA-binding proteins to stimulate the transcription
of prosurvival genes (Chen et al., 2001; Voskas et al.,
2010). Outside the nucleus, PP1 enhances β-catenin nuclear
transcription signaling by dephosphorylating axin-I. This event
prevents the formation of the cytoplasmic β-catenin destruction
complex, leading to accumulation and nuclear translocation
of β-catenin (Luo et al., 2007). Interestingly, expression of
a specific tau isoform (2N4R) in HEK293 and N2a cells
attenuated apoptotic responses elicited by GSK3β overexpression
or by treatment with the kinase inhibitor staurosporine. This
protective, prosurvival effect of 2N4R tau was associated with
reduced phosphorylation and enhanced nuclear translocation of
β-catenin in cells (Li et al., 2007). The physiological relevance of
these data remains to be established, but it appears consistent
with a potential mechanism where tau-mediated activation of
PP1 in the cytoplasm would impact nuclear β-catenin signaling
(Figure 3).
Early studies documenting localization of tau in the nucleus
implied a potential role of this protein in the control of
nuclear activities, but such roles remain largely elusive (Loomis
et al., 1990; Brady et al., 1995; Thurston et al., 1996). More
recently, various studies documented interactions between tau
and nuclear resident proteins such as TIP5, and roles for
tau in heterochromatin stability, repression of ribosomal DNA
transcription, and protection of DNA from stress-induced
damage were proposed (Li et al., 2007; Mansuroglu et al., 2016).
Inside the nucleus, PP1 regulates signaling pathways involved
in the control of gene transcription, splicing, and cell-cycle
progression (Rebelo et al., 2015). For instance, PP1 decreased
cAMP-dependent gene expression by dephosphorylating a
FIGURE 3 | Tau may control multiple signaling pathways in the nucleus. β-catenin degradation/signaling is regulated by the assembly or disassembly of a
cytoplasmic destruction complex [composed of glycogen synthase kinase-3β (GSK3β), casein kinase 1 (CK1), adenomatous polyposis coli (APC), and axin-I].
Whether β-catenin is free to translocate into the nucleus (anti-apoptotic conditions) or degraded in the cytoplasm through ubiquitination (Ub; in pro-apoptotic
conditions) is driven, at least in part, by the phosphorylation status of axin-I. PP1 directly regulates axin-I phosphorylation with PP1-dependent dephosphorylation of
axin-I preventing the formation of the destruction complex and favoring anti-apoptotic β-catenin signaling in the nucleus. Through interactions via its PAD domain,
cytoplasmic tau may activate PP1 (marked by a red asterisk) and promote axin-I dephosphorylation (indicated by a red question mark), but this potential mechanism
awaits further investigation. Similarly, the co-location of tau and PP1 within the nucleus suggests a potential role may exist for tau to modulate intra-nuclear
PP1-dependent pathways such as cAMP response element-binding protein phosphorylation and signaling and/or mRNA splicing. However, future studies are
needed to fully elucidate potential intra-nuclear tau signaling mechanisms (indicated by a red question mark).
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specific residue (Ser133) in cAMP-responsive element-binding
protein (CREB; Hagiwara et al., 1992). PP1 facilitates splicing
of pre-mRNAs by dephosphorylating spliceosome-associated
protein 155 (SAP155; Rebelo et al., 2015) via an interaction
facilitated by a nuclear inhibitor of protein phosphatase 1
(NIPP1). Furthermore, PP1 activity is required for the successful
execution of pre-mRNA splicing (Mermoud et al., 1992).
Considering the nuclear localization of tau and the functional
interaction between tau and PP1 elsewhere in neurons, it
is reasonable to speculate that tau-mediated PP1 activation
could regulate signaling pathways in this compartment. Specific
mechanisms linking tau to nuclear processes and potential
routes through which pathogenic tau species might impair such
processes warrant further investigation.
TAU MODULATION OF SIGNALING
PATHWAYS IN OLIGODENDROCYTES
Myelination of axons requires strict spatiotemporal regulation of
myelin basic protein (MBP) mRNA translation at the axon-glia
interface (White et al., 2008). In oligodendrocytes, MBP mRNA
binds to heterogeneous nuclear ribonucleoprotein A2 (hnRNP
A2) in mRNA transport granules, undergoing anterograde
transport from the nucleus to oligodendrocyte processes in a
translationally silent state (White et al., 2008; Müller et al.,
2013). After initial contact points between oligodendrocytes
and axons are established, Fyn kinase is activated by a β1-
integrin-dependent signal transduction cascade. Consequently,
Fyn phosphorylates hnRNP A2, reducing binding to MBP
mRNA and dismantling RNA transport granules, which in turn
allows local translation of MBP protein (White et al., 2008;
Müller et al., 2013). The role of Fyn kinase in myelination and
interactions between tau and Fyn suggest tau may impact this
process in oligodendrocytes (Figure 4).
Tau is expressed at significant levels in oligodendrocytes
(LoPresti, 2002, 2018) where it can form a complex with
Fyn and α-tubulin and/or potentially actin (Lee et al.,
1998; Klein et al., 2002). Seiberlich and colleagues reported
that tau silencing prevented MBP mRNA transport in
oligodendrocyte processes. Additionally, the absence of tau
significantly reduced interaction between α-tubulin and Fyn
(Seiberlich et al., 2015), suggesting that tau may act as a
scaffold by linking Fyn to MTs in oligodendrocytes. Similar
observations were made using a truncated form of wild-type
tau (∆tau, amino acids 1-228), which maintains the interaction
with Fyn but lacks the microtubule-binding repeat domain
FIGURE 4 | Tau modulates Fyn kinase pathways in myelinating oligodendrocytes. Myelination requires the outgrowth of oligodendrocyte processes and the
formation of contact points between oligodendrocytes and axons. For this to occur, the mRNA of the myelin basic protein (MBP) needs to be targeted to those
contact points. Tau acts as a scaffold protein linking Fyn kinase to the microtubule (MT) cytoskeleton of oligodendrocyte processes. Upon establishment of contact
points at the neuron-glia interface, a signaling cascade involving tau and Fyn kinase is activated. That signaling pathway culminates into the rearrangement of the cell
cytoskeleton that leads MBP mRNA to myelination sites and promotes the growth of oligodendrocyte processes.
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(Belkadi and LoPresti, 2008). CG-4 cells overexpressing ∆tau
displayed a shortening of oligodendrocyte processes along with
mislocalization of Fyn to the cell body instead of processes.
Furthermore, transplanting CG-4 cells that stably express ∆tau
into the spinal cord of amyelin-deficient rat model demonstrated
a failure in myelination capacity (Belkadi and LoPresti, 2008).
In transgenic mice expressing ∆tau, oligodendrocytes displayed
reduced myelination and the animals developed motor deficits
(LoPresti, 2015). Together, these findings suggest that tau
acts as a scaffold protein that targets Fyn kinase to MTs
in oligodendrocyte processes, and that disruption of this
function may impair mechanisms contributing to myelination
(LoPresti, 2018).
TAU MODULATION OF SIGNALING
PATHWAYS ACTIVATED BY INSULIN AND
NEUROTROPHIN RECEPTORS
Early studies involving immunostaining of cultured
neurons documented a fraction of tau close to the plasma
membrane of developing neurites, but functional roles at this
subcellular location, largely devoid of MTs, remained elusive
(Papasozomenos and Binder, 1987; Loomis et al., 1990; Brandt
et al., 1995). Emerging evidence, succinctly discussed below,
revealed modulatory effects of tau on signaling pathways
triggered by insulin and neurotrophin receptors at this location,
potentially shedding some light on this issue.
Signaling pathways activated by insulin play an important
role in the maintenance of neuronal function and peripheral
metabolism (Lee et al., 2016). Although typically associated
with diabetes mellitus, alterations in insulin pathway signaling
are also observed in AD, and a high rate of comorbidity
is observed between AD and diabetes (Ott et al., 1999;
Talbot et al., 2012). Insulin-related signaling is initiated
upon insulin hormone binding to insulin receptors (IR).
IRs are transmembrane tyrosine kinase receptors that
phosphorylate themselves and other downstream substrates,
including insulin receptor substrates (IRS1/2). IRS1/2 activate
phosphatidylinositol 3-kinase (PI3K) which in turn
phosphorylates phosphatidylinositol (3,4)-biphosphate (PIP2) to
convert it into phosphatidylinositol (3,4,5)-triphosphate (PIP3).
PIP3 recruits AKT to the cell membrane where it is activated
and phosphorylates numerous kinase substrates (i.e., GSK3β,
mTORC1, et cetera) that in turn regulate a multitude of
cellular processes. Phosphatase and tensin homolog (PTEN)
dephosphorylates PIP3, providing a mechanism to terminate
insulin-dependent signaling.
Several studies have linked insulin signaling pathway
dysfunction to abnormal phosphorylation of tau (El Khoury
et al., 2014). However, recent evidence also suggests that
tau might modulate this pathway, a notion with important
implications for normal and pathological tau functions. Genetic
deletion of MAPT impaired insulin signaling by disrupting
IRS-1 function and downstream PI3K-AKT-mTOR signaling
(Marciniak et al., 2017). While these changes occurred
in the brain, tau knockout mice also displayed peripheral
hyperinsulinemia, glucose intolerance, and an attenuated food
intake response to insulin treatment (Marciniak et al., 2017).
Providing a potential molecular mechanism for this phenotype,
tau interacted with PTEN via its proline-rich domain and
reduced its lipid phosphatase activity (Marciniak et al., 2017; Tai
et al., 2020). Accordingly, PTEN knockdown restored normal
insulin signaling response in Tau KO mouse neurons suggesting
that tau inhibits PTEN activity in physiological conditions.
Extending these findings to tauopathy models, the accumulation
of mutant P301L tau was associated with increased PTEN
activation in the rTg4510 tau transgenic mouse model, which
in turn contributed to synaptic degeneration (Benetatos et al.,
2020). Together, these studies provide evidence that in normal
conditions tau promotes PI3K-AKT signaling by inhibiting
PTEN directly or indirectly, further suggesting that pathological
modifications in tau that affect this interaction may promote
synaptic dysfunction (Figure 5).
A wide range of extracellular and intracellular stimuli,
including growth factors, hormones, and cytokines, trigger
activation of mitogen-activated protein kinases (MAPKs) to
regulate cell differentiation, survival, and death (Keshet and
Seger, 2010). In neurons, activation of MAPKs by insulin
and neurotrophic factor receptors (Trks) is linked to synaptic
plasticity and survival, among many other cellular processes
(Sun and Nan, 2017). Like IRs, Trks undergo tyrosine
autophosphorylation upon binding to their neurotrophic ligand,
an event that triggers interactions among Trks and various
SH2 domain-containing effector proteins. Among these is
Src homology phosphatase 2 (SHP2), a protein tyrosine
phosphatase also known as PTPN11. SHP2 promotes activation
of extracellular receptor kinases (ERKs), a specific subset
of MAPKs critically involved in neurotrophin-based survival
(Easton et al., 2006).
Various reports documented modulatory effects of tau on
neurotrophin-based activation of MAPK signaling (Figure 5).
For example, deletion of tau in PC12 cells impaired ERK
activation and neurite outgrowth induced by nerve growth
factor (NGF) stimuli (Leugers and Lee, 2010). Interestingly,
the phosphorylation status of tau impacted the response. Tau
phosphorylation at T231 potentiated NGF-induced activation
of ERK1/2 kinases, whereas phosphorylation at S214 or the
PHF1 site (S396/S404) inhibited this signaling (Leugers and
Lee, 2010; Leugers et al., 2013). Additional work suggested
that these effects might involve a direct, activating protein-
protein interaction between tau and SHP2 (Kim et al., 2019).
Tau and SHP2 interacted in pulldown assays and both
proteins were identified as components of a larger protein
complex using proximity ligation assays (Kim et al., 2019).
Pseudophosphorylation at T231 in tau enhanced the interaction
with SHP2 in cells compared to T231A tau (Kim et al.,
2019). Evidence from human tissue studies suggests tau-SHP2
interactions are increased in mild cognitive impairment and in
AD brains when compared to non-demented control brains (Kim
et al., 2019). Additionally, tau interacts with the SH3 domain
of an SHP2-activator protein, Grb2, but whether SHP2 and
Grb2 interact simultaneously with tau and the functional
implications of these interactions are not yet well-defined
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FIGURE 5 | Tau promotes signal transduction of insulin and neurotrophic factor pathways. Neurotrophic factors (NTF) and insulin activate specific receptor tyrosine
kinases (Trks and IRs, respectively). Following autophosphorylation, the receptors initiate signaling through multiple downstream pathways, two of which are partially
modulated by tau. Activation of AKT signaling by PI3K is regulated by PIP3 levels, increased through phosphorylation by PI3K and decreased through
dephosphorylation by PTEN. Tau reportedly binds to PTEN directly to inhibit its phosphatase activity (red inhibitory arrow), thereby promoting AKT activation. Tau can
also promote MAPK signaling through an interaction with SHP2, a tyrosine phosphatase downstream of the receptor tyrosine kinases. Tau also interacts with the
SH3 domain of Grb2, an activator of SHP2 but whether tau, SHP2, and Grb2 form a complex and the downstream effects are not known (indicated by a red
question mark). Phosphorylation at specific residues may impact the modulatory role of tau on these pathways.
(Reynolds et al., 2008). Considered together, these data suggest
that tau may modulate neurotrophin-induced activation of the
MAPK signaling pathway, but whether such effects involve direct
activation of SHP2 by tau directly or targeted localization to lipid
rafts awaits further investigation.
CONCLUSIONS
The long-held hypothesis that stabilization of MTs represents
tau’s primary biological function is being increasingly challenged
by a growing body of independent experimental evidence.
Continuing to challenge this dogma will help expand our
interpretation of such evidence and advance our understanding
of tau biology in health and disease conditions. For example,
the ability of tau to interact with MTs may reflect just one of
several features enabling a much more diverse set of functions
by this protein, such as the regulation of phosphorylation-
based signaling pathways in axons and other MT-rich subcellular
compartments. On the other hand,MT-independent interactions
with additional proteins may facilitate similar functions in
modulating pathways in other compartments featuring few or
no MTs. This notion appears consistent with tau’s widespread
subcellular distribution, its highly dynamic conformational
flexibility, and the numerous kinase and phosphatase binding
partners identified thus far. Based on these characteristics, we
posit that tau functions as a signaling hub, regulating a wide
set of cellular processes through the modulation of selected
kinases and phosphatases. This function in turn appears to
be impacted by specific modification events in tau, including
mutations, phosphorylation, truncation, and aggregation, which
could have important implications for physiological and disease
states. A more dynamic perspective of tau as a multifaceted
protein involved in the control of intracellular signaling may also
provide a novel framework for the development of therapeutic
approaches to treat tauopathies.
AUTHOR CONTRIBUTIONS
RM, BC, MA, SB, GM, and NK each contributed to writing and
editing this review. All authors contributed to the article and
approved the submitted version.
FUNDING
This work was supported by NIH grants (R01AG067762 and
R01AG044372 to NK, R01NS082730 to NK and SB,
R01NS118177 and R21NS120126 to GM, R01NS023868
and R01NS041170 to SB), a gift from Neurodegenerative
Frontiers in Molecular Neuroscience | www.frontiersin.org 10 March 2021 | Volume 14 | Article 647054
Mueller et al. Tau as a Signaling Hub
Research Inc. (GM), a Zenith Award from the Alzheimer’s
Association (SB), a grant from the Secchia Family Foundation
(NK), NIH/National Institute on Aging (NIA) funded Michigan
Alzheimer’s Disease Research Center 5P30AG053760 (BC), the
Office of the Assistant Secretary of Defense for Health Affairs
through the Peer-Reviewed Alzheimer’s Research Program
(Award No. W81XWH-20-1-0174 to BC), and an Alzheimer’s
Association Research Grant 20-682085 (BC).
REFERENCES
Ahmed, T., Van der Jeugd, A., Blum, D., Galas, M. C., D’Hooge, R., Buee, L.,
et al. (2014). Cognition and hippocampal synaptic plasticity in mice with
a homozygous tau deletion. Neurobiol. Aging 35, 2474–2478. doi: 10.1016/j.
neurobiolaging.2014.05.005
Belkadi, A., and LoPresti, P. (2008). Truncated Tau with the Fyn-binding domain
and without the microtubule-binding domain hinders the myelinating capacity
of an oligodendrocyte cell line. J. Neurochem. 107, 351–360. doi: 10.1111/j.
1471-4159.2008.05600.x
Benetatos, J., Bennett, R. E., Evans, H. T., Ellis, S. A., Hyman, B. T., Bodea, L. G.,
et al. (2020). PTEN activation contributes to neuronal and synaptic engulfment
by microglia in tauopathy. Acta Neuropathol. 140, 7–24. doi: 10.1007/s00401-
020-02151-9
Bhaskar, K., Yen, S.-H., and Lee, G. (2005). Disease-related modifications in tau
affect the interaction between Fyn and Tau. J. Biol. Chem. 280, 35119–35125.
doi: 10.1074/jbc.M505895200
Black, M. M. (2016). Axonal transport: the orderly motion of axonal structures.
Methods Cell Biol. 131, 1–19. doi: 10.1016/bs.mcb.2015.06.001
Black, M. M., Slaughter, T., Moshiach, S., Obrocka, M., and Fischer, I. (1996). Tau
is enriched on dynamic microtubules in the distal region of growing axons.
J. Neurosci. 16, 3601–3619. doi: 10.1523/JNEUROSCI.16-11-03601.1996
Bliss, T. V., Collingridge, G. L., Morris, R. G., and Reymann, K. G. (2018). Long-
term potentiation in the hippocampus: discovery, mechanisms and function.
Neuroforum 24, A103–A120. doi: 10.1515/nf-2017-a059
Brady, S. T., and Morfini, G. A. (2017). Regulation of motor proteins, axonal
transport deficits and adult-onset neurodegenerative diseases. Neurobiol. Dis.
105, 273–282. doi: 10.1016/j.nbd.2017.04.010
Brady, R. M., Zinkowski, R. P., and Binder, L. I. (1995). Presence of tau in isolated
nuclei from human brain. Neurobiol. Aging 16, 479–486. doi: 10.1016/0197-
4580(95)00023-8
Brandt, R., Léger, J., and Lee, G. (1995). Interaction of tau with the neural plasma
membrane mediated by tau’s amino-terminal projection domain. J. Cell Biol.
131, 1327–1340. doi: 10.1083/jcb.131.5.1327
Brandt, R., Trushina, N. I., and Bakota, L. (2020). Much more than a cytoskeletal
protein: physiological and pathological functions of the non-microtubule
binding region of tau. Front. Neurol. 11:590059. doi: 10.3389/fneur.2020.
590059
Buday, L., and Tompa, P. (2010). Functional classification of scaffold proteins
and related molecules. FEBS J. 277, 4348–4355. doi: 10.1111/j.1742-4658.2010.
07864.x
Carmel, G., Mager, E. M., Binder, L. I., and Kuret, J. (1996). The structural basis
of monoclonal antibody Alz50’s selectivity for Alzheimer’s disease pathology.
J. Biol. Chem. 271, 32789–32795. doi: 10.1074/jbc.271.51.32789
Carnegie, G. K., and Scott, J. D. (2003). A-kinase anchoring proteins and neuronal
signaling mechanisms. Genes Dev. 17, 1557–1568. doi: 10.1101/gad.1095803
Chen, S., Guttridge, D. C., You, Z., Zhang, Z., Fribley, A., Mayo, M. W., et al.
(2001). Wnt-1 signaling inhibits apoptosis by activating β-catenin/T cell factor-
mediated transcription. J. Cell Biol. 152, 87–96. doi: 10.1083/jcb.152.1.87
Cleveland, D.W., Hwo, S. Y., and Kirschner, M.W. (1977a). Physical and chemical
properties of purified tau factor and the role of tau in microtubule assembly.
J. Mol. Biol. 116, 227–247. doi: 10.1016/0022-2836(77)90214-5
Cleveland, D. W., Hwo, S. Y., and Kirschner, M. W. (1977b). Purification of tau,
a microtubule-associated protein that induces assembly of microtubules from
purified tubulin. J. Mol. Biol. 116, 207–225. doi: 10.1016/0022-2836(77)90213-3
Combs, B., Hamel, C., and Kanaan, N. M. (2016). Pathological conformations
involving the amino terminus of tau occur early in Alzheimer’s disease and
are differentially detected by monoclonal antibodies. Neurobiol. Dis. 94, 18–31.
doi: 10.1016/j.nbd.2016.05.016
Combs, B., and Kanaan, N. M. (2017). Exposure of the amino terminus of tau is
a pathological event in multiple tauopathies. Am. J. Pathol. 187, 1222–1229.
doi: 10.1016/j.ajpath.2017.01.019
Cox, K., Combs, B., Abdelmesih, B., Morfini, G., Brady, S. T., and Kanaan, N. M.
(2016). Analysis of isoform-specific tau aggregates suggests a common toxic
mechanism involving similar pathological conformations and axonal transport
inhibition. Neurobiol. Aging 47, 113–126. doi: 10.1016/j.neurobiolaging.2016.
07.015
Dawson, H. N., Ferreira, A., Eyster, M. V., Ghoshal, N., Binder, L. I., and
Vitek, M. P. (2001). Inhibition of neuronal maturation in primary hippocampal
neurons from tau deficient mice. J. Cell Sci. 114, 1179–1187.
DiTella, M., Feiguin, F., Morfini, G., and Caceres, A. (1994). Microfilament-
associated growth cone component depends upon tau for its intracellular
localization. Cell Motil. Cytoskeleton 29, 117–130. doi: 10.1002/cm.970290204
Easton, J. B., Royer, A. R., and Middlemas, D. S. (2006). The protein tyrosine
phosphatase, Shp2, is required for the complete activation of the RAS/MAPK
pathway by brain-derived neurotrophic factor. J. Neurochem. 97, 834–845.
doi: 10.1111/j.1471-4159.2006.03789.x
El Khoury, N. B., Gratuze, M., Papon, M. A., Bretteville, A., and Planel, E.
(2014). Insulin dysfunction and tau pathology. Front. Cell. Neurosci. 8:22.
doi: 10.3389/fncel.2014.00022
Fá, M., Puzzo, D., Piacentini, R., Staniszewski, A., Zhang, H., Baltrons, M. A., et al.
(2016). Extracellular tau oligomers produce an immediate impairment of LTP
and memory. Sci. Rep. 6:19393. doi: 10.1038/srep19393
Fitzpatrick, A. W. P., Falcon, B., He, S., Murzin, A. G., Murshudov, G.,
Garringer, H. J., et al. (2017). Cryo-EM structures of tau filaments from
Alzheimer’s disease. Nature 547, 185–190. doi: 10.1038/nature23002
Frandemiche, M. L., De Seranno, S., Rush, T., Borel, E., Elie, A., Arnal, I., et al.
(2014). Activity-dependent tau protein translocation to excitatory synapse is
disrupted by exposure to amyloid-β oligomers. J. Neurosci. 34, 6084–6097.
doi: 10.1523/JNEUROSCI.4261-13.2014
Gibbs, K. L., Greensmith, L., and Schiavo, G. (2015). Regulation of axonal
transport by protein kinases. Trends Biochem. Sci. 40, 597–610. doi: 10.1016/j.
tibs.2015.08.003
Goedert, M., and Spillantini, M. G. (2019). Ordered assembly of tau protein and
neurodegeneration. Adv. Exp. Med. Biol. 1184, 3–21. doi: 10.1007/978-981-32-
9358-8_1
Götz, J., Xia, D., Leinenga, G., Chew, Y. L., and Nicholas, H. (2013). What renders
TAU toxic. Front. Neurol. 4:72. doi: 10.3389/fneur.2013.00072
Grant, S. G., O’Dell, T. J., Karl, K. A., Stein, P. L., Soriano, P., and Kandel, E. R.
(1992). Impaired long-term potentiation, spatial learning and hippocampal
development in fyn mutant mice. Science 258, 1903–1910. doi: 10.1126/science.
1361685
Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., and
Wisniewski, H. M. (1986). Microtubule-associated protein tau. A component
of Alzheimer paired helical filaments. J. Biol. Chem. 261, 6084–6089.
doi: 10.1016/S0021-9258(17)38495-8
Gunasekaran, K., Tsai, C.-J., Kumar, S., Zanuy, D., and Nussinov, R. (2003).
Extended disordered proteins: targeting function with less scaffold. Trends
Biochem. Sci. 28, 81–85. doi: 10.1016/S0968-0004(03)00003-3
Hagiwara, M., Alberts, A., Brindle, P., Meinkoth, J., Feramisco, J., Deng, T., et al.
(1992). Transcriptional attenuation following cAMP induction requires PP-1-
mediated dephosphorylation of CREB. Cell 70, 105–113. doi: 10.1016/0092-
8674(92)90537-m
Hanger, D. P., Goniotaki, D., and Noble, W. (2019). Synaptic localisation of tau.
Adv. Exp. Med. Biol. 1184, 105–112. doi: 10.1007/978-981-32-9358-8_9
Harada, A., Oguchi, K., Okabe, S., Kuno, J., Terada, S., Ohshima, T., et al. (1994).
Altered microtubule organization in small-calibre axons of mice lacking tau
protein. Nature 369, 488–491. doi: 10.1038/369488a0
Hill, E., Wall, M. J., Moffat, K. G., and Karikari, T. K. (2020). Understanding
the pathophysiological actions of tau oligomers: a critical review of
current electrophysiological approaches. Front. Mol. Neurosci. 13:155.
doi: 10.3389/fnmol.2020.00155
Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., et al.
(2010). Tau mislocalization to dendritic spines mediates synaptic dysfunction
Frontiers in Molecular Neuroscience | www.frontiersin.org 11 March 2021 | Volume 14 | Article 647054
Mueller et al. Tau as a Signaling Hub
independently of neurodegeneration. Neuron 68, 1067–1081. doi: 10.1016/j.
neuron.2010.11.030
Horowitz, P. M., Patterson, K. R., Guillozet-Bongaarts, A. L., Reynolds, M. R.,
Carroll, C. A., Weintraub, S. T., et al. (2004). Early N-terminal changes and
caspase-6 cleavage of tau in Alzheimer’s disease. J. Neurosci. 24, 7895–7902.
doi: 10.1523/JNEUROSCI.1988-04.2004
Ihara, Y. (1986). Alzheimer’s paired helical filaments. Rinsho Shinkeigaku 26,
1287–1289.
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., et al. (2010).
Dendritic function of tau mediates amyloid-β toxicity in Alzheimer’s disease
mouse models. Cell 142, 387–397. doi: 10.1016/j.cell.2010.06.036
Janning, D., Igaev, M., Sundermann, F., Bruhmann, J., Beutel, O., Heinisch, J. J.,
et al. (2014). Single-molecule tracking of tau reveals fast kiss-and-hop
interaction with microtubules in living neurons.Mol. Biol. Cell 25, 3541–3551.
doi: 10.1091/mbc.E14-06-1099
Jeganathan, S., von Bergen, M., Brutlach, H., Steinhoff, H. J., and Mandelkow, E.
(2006). Global hairpin folding of tau in solution. Biochemistry 45, 2283–2293.
doi: 10.1021/bi0521543
Jicha, G. A., Berenfeld, B., and Davies, P. (1999). Sequence requirements
for formation of conformational variants of tau similar to those found in
Alzheimer’s disease. J. Neurosci. Res. 55, 713–723. doi: 10.1002/(SICI)1097-
4547(19990315)55:6<713::AID-JNR6>3.0.CO;2-G
Jicha, G. A., Bowser, R., Kazam, I. G., and Davies, P. (1997). Alz-50 and MC-1,
a new monoclonal antibody raised to paired helical filaments, recognize
conformational epitopes on recombinant tau. J. Neurosci. Res. 48, 128–132.
doi: 10.1002/(sici)1097-4547(19970415)48:2<128::aid-jnr5>3.0.co;2-e
Kanaan, N. M., Cox, K., Alvarez, V. E., Stein, T. D., Poncil, S., and
McKee, A. C. (2016). Characterization of early pathological tau conformations
and phosphorylation in chronic traumatic encephalopathy. J. Neuropathol. Exp.
Neurol. 75, 19–34. doi: 10.1093/jnen/nlv001
Kanaan, N. M., Morfini, G., Pigino, G., LaPointe, N. E., Andreadis, A., Song, Y.,
et al. (2012). Phosphorylation in the amino terminus of tau prevents inhibition
of anterograde axonal transport. Neurobiol. Aging 33, 826.e15–830.e15.
doi: 10.1016/j.neurobiolaging.2011.06.006
Kanaan, N. M., Morfini, G. A., LaPointe, N. E., Pigino, G. F., Patterson, K. R.,
Song, Y., et al. (2011). Pathogenic forms of tau inhibit kinesin-dependent
axonal transport through a mechanism involving activation of axonal
phosphotransferases. J. Neurosci. 31, 9858–9868. doi: 10.1523/JNEUROSCI.
0560-11.2011
Kanaan, N. M., Pigino, G. F., Brady, S. T., Lazarov, O., Binder, L. I., and
Morfini, G. A. (2013). Axonal degeneration in Alzheimer’s disease: when
signaling abnormalities meet the axonal transport system. Exp. Neurol. 246,
44–53. doi: 10.1016/j.expneurol.2012.06.003
Kang, S., Eskandari-Sedighi, G., Hromadkova, L., Safar, J., and Westaway, D.
(2020). Cellular biology of tau diversity and pathogenic conformers. Front.
Neurol. 11:590199. doi: 10.3389/fneur.2020.590199
Keshet, Y., and Seger, R. (2010). The MAP kinase signaling cascades: a system of
hundreds of components regulates a diverse array of physiological functions.
Methods Mol. Biol. 661, 3–38. doi: 10.1007/978-1-60761-795-2_1
Kim, Y., Liu, G., Leugers, C. J., Mueller, J. D., Francis, M. B., Hefti, M. M., et al.
(2019). Tau interacts with SHP2 in neuronal systems and in Alzheimer’s disease
brains. J. Cell Sci. 132:jcs229054. doi: 10.1242/jcs.229054
Kimura, T., Whitcomb, D. J., Jo, J., Regan, P., Piers, T., Heo, S., et al. (2014).
Microtubule-associated protein tau is essential for long-term depression in
the hippocampus. Philos. Trans. R. Soc. Lond. B Biol. Sci. 369:20130144.
doi: 10.1098/rstb.2013.0144
Klein, C., Kramer, E.-M., Cardine, A.-M., Schraven, B., Brandt, R., and Trotter, J.
(2002). Process outgrowth of oligodendrocytes is promoted by interaction
of fyn kinase with the cytoskeletal protein tau. J. Neurosci. 22, 698–707.
doi: 10.1523/JNEUROSCI.22-03-00698.2002
Kneynsberg, A., Combs, B., Christensen, K., Morfini, G., and Kanaan, N. M.
(2017). Axonal degeneration in tauopathies: disease relevance and underlying
mechanisms. Front. Neurosci. 11:572. doi: 10.3389/fnins.2017.00572
Kosik, K. S., Orecchio, L. D., Binder, L., Trojanowski, J. Q., Lee, V. M., and Lee, G.
(1988). Epitopes that span the tau molecule are shared with paired helical
filaments. Neuron 1, 817–825. doi: 10.1016/0896-6273(88)90129-8
LaPointe, N. E., Morfini, G., Pigino, G., Gaisina, I. N., Kozikowski, A. P.,
Binder, L. I., et al. (2009). The amino terminus of tau inhibits
kinesin-dependent axonal transport: implications for filament toxicity.
J. Neurosci. Res. 87, 440–451. doi: 10.1002/jnr.21850
Lau, D. H., Hogseth, M., Phillips, E. C., O’Neill, M. J., Pooler, A. M., Noble, W.,
et al. (2016). Critical residues involved in tau binding to fyn: implications for
tau phosphorylation in Alzheimer’s disease. Acta Neuropathol. Commun. 4:49.
doi: 10.1186/s40478-016-0317-4
Lebouvier, T., Scales, T. M., Hanger, D. P., Geahlen, R. L., Lardeux, B.,
Reynolds, C. H., et al. (2008). The microtubule-associated protein tau is
phosphorylated by Syk. Biochim. Biophys. Acta 1783, 188–192. doi: 10.1016/j.
bbamcr.2007.11.005
Lee, G., and Leugers, C. J. (2012). Tau and tauopathies. Prog. Mol. Biol. Transl. Sci.
107, 263–293. doi: 10.1016/B978-0-12-385883-2.00004-7
Lee, G., Newman, S. T., Gard, D. L., Band, H., and Panchamoorthy, G. (1998).
Tau interacts with src-family non-receptor tyrosine kinases. J. Cell Sci. 111,
3167–3177.
Lee, G., Thangavel, R., Sharma, V.M., Litersky, J. M., Bhaskar, K., Fang, S. M., et al.
(2004). Phosphorylation of tau by fyn: implications for Alzheimer’s disease.
J. Neurosci. 24, 2304–2312. doi: 10.1523/JNEUROSCI.4162-03.2004
Lee, S.-H., Zabolotny, J. M., Huang, H., Lee, H., and Kim, Y.-B. (2016).
Insulin in the nervous system and the mind: functions in metabolism,
memory, and mood. Mol. Metab. 5, 589–601. doi: 10.1016/j.molmet.2016.
06.011
Lester, L. B., and Scott, J. D. (1997). Anchoring and scaffold proteins for kinases
and phosphatases. Recent Prog. Horm. Res. 52, 409–429; discussion 429–430.
Leugers, C. J., Koh, J. Y., Hong, W., and Lee, G. (2013). Tau in MAPK activation.
Front. Neurol. 4:161. doi: 10.3389/fneur.2013.00161
Leugers, C. J., and Lee, G. (2010). Tau potentiates nerve growth factor-induced
mitogen-activated protein kinase signaling and neurite initiation without
a requirement for microtubule binding. J. Biol. Chem. 285, 19125–19134.
doi: 10.1074/jbc.M110.105387
Li, H.-L., Wang, H.-H., Liu, S.-J., Deng, Y.-Q., Zhang, Y.-J., Tian, Q., et al.
(2007). Phosphorylation of tau antagonizes apoptosis by stabilizing β-catenin,
a mechanism involved in Alzheimer’s neurodegeneration. Proc. Natl. Acad. Sci.
U S A 104, 3591–3596. doi: 10.1073/pnas.0609303104
Liao, H., Li, Y., Brautigan, D. L., and Gundersen, G. G. (1998). Protein phosphatase
1 is targeted to microtubules by the microtubule-associated protein tau. J. Biol.
Chem. 273, 21901–21908. doi: 10.1074/jbc.273.34.21901
Liu, C. W., Lee, G., and Jay, D. G. (1999). Tau is required for neurite outgrowth
and growth cone motility of chick sensory neurons. Cell Motil. Cytoskeleton
43, 232–242. doi: 10.1002/(SICI)1097-0169(1999)43:3<232::AID-CM6>3.0.
CO;2-7
Loomis, P. A., Howard, T. H., Castleberry, R. P., and Binder, L. I. (1990).
Identification of nuclear tau isoforms in human neuroblastoma cells. Proc. Natl.
Acad. Sci. U S A 87, 8422–8426. doi: 10.1073/pnas.87.21.8422
LoPresti, P. (2002). Regulation and differential expression of tau mRNA isoforms
as oligodendrocytes mature in vivo: implications for myelination. Glia 37,
250–257. doi: 10.1002/glia.10035
LoPresti, P. (2015). Inducible expression of a truncated form of tau in
oligodendrocytes elicits gait abnormalities and a decrease in myelin:
implications for selective CNS degenerative diseases. Neurochem. Res. 40,
2188–2199. doi: 10.1007/s11064-015-1707-x
LoPresti, P. (2018). Tau in oligodendrocytes takes neurons in sickness and in
health. Int. J. Mol. Sci. 19:2408. doi: 10.3390/ijms19082408
Luo, W., Peterson, A., Garcia, B. A., Coombs, G., Kofahl, B., Heinrich, R., et al.
(2007). Protein phosphatase 1 regulates assembly and function of the β-catenin
degradation complex. EMBO J. 26, 1511–1521. doi: 10.1038/sj.emboj.7601607
Lüscher, C., and Malenka, R. C. (2012). NMDA receptor-dependent long-term
potentiation and long-term depression (LTP/LTD). Cold Spring Harb. Perspect.
Biol. 4:a005710. doi: 10.1101/cshperspect.a005710
Maina, M. B., Al-Hilaly, Y. K., and Serpell, L. C. (2016). Nuclear
tau and its potential role in Alzheimer’s disease. Biomolecules 6:9.
doi: 10.3390/biom6010009
Mandelkow, E. M., and Mandelkow, E. (2012). Biochemistry and cell biology of
tau protein in neurofibrillary degeneration. Cold Spring Harb. Perspect. Med.
2:a006247. doi: 10.1101/cshperspect.a006247
Mandell, J. W., and Banker, G. A. (1995). The microtubule cytoskeleton and the
development of neuronal polarity. Neurobiol. Aging 16, 229–237; discussion
238. doi: 10.1016/0197-4580(94)00164-v
Frontiers in Molecular Neuroscience | www.frontiersin.org 12 March 2021 | Volume 14 | Article 647054
Mueller et al. Tau as a Signaling Hub
Mansuroglu, Z., Benhelli-Mokrani, H., Marcato, V., Sultan, A., Violet, M.,
Chauderlier, A., et al. (2016). Loss of Tau protein affects the structure,
transcription and repair of neuronal pericentromeric heterochromatin. Sci.
Rep. 6:33047. doi: 10.1038/srep33047
Marciniak, E., Leboucher, A., Caron, E., Ahmed, T., Tailleux, A., Dumont, J.,
et al. (2017). Tau deletion promotes brain insulin resistance. J. Exp. Med. 214,
2257–2269. doi: 10.1084/jem.20161731
McInnes, J., Wierda, K., Snellinx, A., Bounti, L., Wang, Y.-C., Stancu, I.-C.,
et al. (2018). Synaptogyrin-3 mediates presynaptic dysfunction induced by tau.
Neuron 97, 823.e8–835.e8. doi: 10.1016/j.neuron.2018.01.022
Mermoud, J. E., Cohen, P., and Lamond, A. I. (1992). Ser/Thr-specific protein
phosphatases are required for both catalytic steps of pre-mRNA splicing.
Nucleic Acids Res. 20, 5263–5269. doi: 10.1093/nar/20.20.5263
Min, S.-W., Chen, X., Tracy, T. E., Li, Y., Zhou, Y., Wang, C., et al. (2015). Critical
role of acetylation in tau-mediated neurodegeneration and cognitive deficits.
NatMed 21, 1154–1162. doi: 10.1038/nm.3951
Miyamoto, T., Stein, L., Thomas, R., Djukic, B., Taneja, P., Knox, J., et al. (2017).
Phosphorylation of tau at Y18, but not tau-fyn binding, is required for tau
to modulate NMDA receptor-dependent excitotoxicity in primary neuronal
culture.Mol. Neurodegener. 12:41. doi: 10.1186/s13024-017-0176-x
Moreno, H., Morfini, G., Buitrago, L., Ujlaki, G., Choi, S., Yu, E., et al. (2016).
Tau pathology-mediated presynaptic dysfunction. Neuroscience 325, 30–38.
doi: 10.1016/j.neuroscience.2016.03.044
Morfini, G. A., Burns, M., Binder, L. I., Kanaan, N. M., LaPointe, N.,
Bosco, D. A., et al. (2009). Axonal transport defects in neurodegenerative
diseases. J. Neurosci. 29, 12776–12786. doi: 10.1523/JNEUROSCI.3463-
09.2009
Morfini, G., Schmidt, N., Weissmann, C., Pigino, G., and Kins, S. (2016).
Conventional kinesin: biochemical heterogeneity and functional implications
in health and disease. Brain Res. Bull. 126, 347–353. doi: 10.1016/j.brainresbull.
2016.06.009
Morfini, G., Szebenyi, G., Brown, H., Pant, H. C., Pigino, G., DeBoer, S., et al.
(2004). A novel CDK5-dependent pathway for regulating GSK3 activity and
kinesin-driven motility in neurons. EMBO J. 23, 2235–2245. doi: 10.1038/sj.
emboj.7600237
Morfini, G., Szebenyi, G., Elluru, R., Ratner, N., and Brady, S. T. (2002). Glycogen
synthase kinase 3 phosphorylates kinesin light chains and negatively regulates
kinesin-based motility. EMBO J. 21, 281–293. doi: 10.1093/emboj/21.3.281
Morfini, G., Szebenyi, G., Richards, B., and Brady, S. T. (2001). Regulation of
kinesin: implications for neuronal development. Dev. Neurosci. 23, 364–376.
doi: 10.1159/000048720
Morris, M., Maeda, S., Vossel, K., and Mucke, L. (2011). The many faces of tau.
Neuron 70, 410–426. doi: 10.1016/j.neuron.2011.04.009
Morris, S. L., Tsai, M.-Y., Aloe, S., Bechberger, K., Konig, S., Morfini, G.,
et al. (2020). Defined tau phosphospecies differentially inhibit fast axonal
transport through activation of two independent signaling pathways. Front.
Mol. Neurosci. 13:610037. doi: 10.3389/fnmol.2020.610037
Müller, C., Bauer, N. M., Schäfer, I., and White, R. (2013). Making myelin basic
protein-from mRNA transport to localized translation. Front. Cell. Neurosci.
7:169. doi: 10.3389/fncel.2013.00169
Nakazawa, T., Komai, S., Tezuka, T., Hisatsune, C., Umemori, H., Semba, K., et al.
(2001). Characterization of Fyn-mediated tyrosine phosphorylation sites on
GluR epsilon 2 (NR2B) subunit of the N-methyl-D-aspartate receptor. J. Biol.
Chem. 276, 693–699. doi: 10.1074/jbc.M008085200
Ondrejcak, T., Klyubin, I., Corbett, G. T., Fraser, G., Hong, W., Mably, A. J.,
et al. (2018). Cellular prion protein mediates the disruption of hippocampal
synaptic plasticity by soluble tau in vivo. J. Neurosci. 38, 10595–10606.
doi: 10.1523/JNEUROSCI.1700-18.2018
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A., Hofman, A., and Breteler, M.M.
(1999). Diabetes mellitus and the risk of dementia: the Rotterdam study.
Neurology 53, 1937–1942. doi: 10.1212/wnl.53.9.1937
Padmanabhan, P., Martínez-Mármol, R., Xia, D., Götz, J., and Meunier, F. A.
(2019). Frontotemporal dementia mutant Tau promotes aberrant
Fyn nanoclustering in hippocampal dendritic spines. eLife 8:e45040.
doi: 10.7554/eLife.45040
Papasozomenos, S. C., and Binder, L. I. (1987). Phosphorylation determines two
distinct species of Tau in the central nervous system. Cell Motil. Cytoskeleton 8,
210–226. doi: 10.1002/cm.970080303
Patterson, K. R.,Ward, S.M., Combs, B., Voss, K., Kanaan, N.M.,Morfini, G., et al.
(2011). Heat shock protein 70 prevents both tau aggregation and the inhibitory
effects of preexisting tau aggregates on fast axonal transport. Biochemistry 50,
10300–10310. doi: 10.1021/bi2009147
Pérez, M. J., Jara, C., and Quintanilla, R. A. (2018). Contribution of tau pathology
to mitochondrial impairment in neurodegeneration. Front. Neurosci. 12:441.
doi: 10.3389/fnins.2018.00441
Puzzo, D., Piacentini, R., Fá, M., Gulisano, W., Li Puma, D. D., Staniszewski, A.,
et al. (2017). LTP and memory impairment caused by extracellular Aβ and Tau
oligomers is APP-dependent. eLife 6:e26991. doi: 10.7554/eLife.26991
Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P., and Ferreira, A. (2002).
Tau is essential to β -amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci.
U S A 99, 6364–6369. doi: 10.1073/pnas.092136199
Ratner, N., Bloom, G. S., and Brady, S. T. (1998). A role for cyclin-dependent
kinase(s) in the modulation of fast anterograde axonal transport: effects
defined by olomoucine and the APC tumor suppressor protein. J. Neurosci. 18,
7717–7726. doi: 10.1523/JNEUROSCI.18-19-07717.1998
Rebelo, S., Santos, M., Martins, F., da Silva, E. F. E., and da Cruz e Silva, O. A.
(2015). Protein phosphatase 1 is a key player in nuclear events. Cell. Signal. 27,
2589–2598. doi: 10.1016/j.cellsig.2015.08.007
Regan, P., Piers, T., Yi, J.-H., Kim, D.-H., Huh, S., Park, S. J., et al. (2015).
Tau phosphorylation at serine 396 residue is required for hippocampal LTD.
J. Neurosci. 35, 4804–4812. doi: 10.1523/JNEUROSCI.2842-14.2015
Reynolds, C. H., Garwood, C. J., Wray, S., Price, C., Kellie, S., Perera, T.,
et al. (2008). Phosphorylation regulates tau interactions with Src homology
3 domains of phosphatidylinositol 3-kinase, phospholipase Cγ1, Grb2, and Src
family kinases. J. Biol. Chem. 283, 18177–18186. doi: 10.1074/jbc.M709715200
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., et al.
(2007). Reducing endogenous tau ameliorates amyloid β-induced deficits in an
Alzheimer’s disease mouse model. Science 316, 750–754. doi: 10.1126/science.
1141736
Roche, K. W., Standley, S., McCallum, J., Dune Ly, C., Ehlers, M. D.,
and Wenthold, R. J. (2001). Molecular determinants of NMDA receptor
internalization. Nat. Neurosci. 4, 794–802. doi: 10.1038/90498
Rong, Y., Lu, X., Bernard, A., Khrestchatisky, M., and Baudry, M. (2001). Tyrosine
phosphorylation of ionotropic glutamate receptors by Fyn or Src differentially
modulates their susceptibility to calpain and enhances their binding to spectrin
and PSD-95. J. Neurochem. 79, 382–390. doi: 10.1046/j.1471-4159.2001.
00565.x
Rovelet-Lecrux, A., Lecourtois, M., Thomas-Anterion, C., Le Ber, I., Brice, A.,
Frebourg, T., et al. (2009). Partial deletion of the MAPT gene: a novel
mechanism of FTDP-17. Hum. Mutat. 30, E591–E602. doi: 10.1002/humu.
20979
Sabbagh, J. J., andDickey, C. A. (2016). Themetamorphic nature of the tau protein:
dynamic flexibility comes at a cost. Front. Neurosci. 10:3. doi: 10.3389/fnins.
2016.00003
Seiberlich, V., Bauer, N. G., Schwarz, L., Ffrench-Constant, C., Goldbaum, O., and
Richter-Landsberg, C. (2015). Downregulation of the microtubule associated
protein tau impairs process outgrowth and myelin basic protein mRNA
transport in oligodendrocytes. Glia 63, 1621–1635. doi: 10.1002/glia.22832
Sengupta, S., Horowitz, P. M., Karsten, S. L., Jackson, G. R., Geschwind, D. H.,
Fu, Y., et al. (2006). Degradation of tau protein by puromycin-
sensitive aminopeptidase in vitro. Biochemistry 45, 15111–15119.
doi: 10.1021/bi061830d
Sharma, V. M., Litersky, J. M., Bhaskar, K., and Lee, G. (2007). Tau impacts
on growth-factor-stimulated actin remodeling. J. Cell Sci. 120, 748–757.
doi: 10.1242/jcs.03378
Shaw, A. S., and Filbert, E. L. (2009). Scaffold proteins and immune-cell signalling.
Nat. Rev. Immunol. 9, 47–56. doi: 10.1038/nri2473
Sinsky, J., Majerova, P., Kovac, A., Kotlyar, M., Jurisica, I., and Hanes, J. (2020).
Physiological tau interactome in brain and its link to tauopathies. J. Proteome
Res. 19, 2429–2442. doi: 10.1021/acs.jproteome.0c00137
Smith, F. D., Langeberg, L. K., and Scott, J. D. (2006). The where’s and when’s of
kinase anchoring. Trends Biochem. Sci. 31, 316–323. doi: 10.1016/j.tibs.2006.
04.009
Song, Y., Kang, M., Morfini, G., and Brady, S. T. (2016). Fast axonal transport in
isolated axoplasm from the squid giant axon. Methods Cell Biol. 131, 331–348.
doi: 10.1016/bs.mcb.2015.07.004
Frontiers in Molecular Neuroscience | www.frontiersin.org 13 March 2021 | Volume 14 | Article 647054
Mueller et al. Tau as a Signaling Hub
Sontag, E., Nunbhakdi-Craig, V., Lee, G., Brandt, R., Kamibayashi, C., Kuret, J.,
et al. (1999). Molecular interactions among protein phosphatase 2A, tau, and
microtubules. Implications for the regulation of tau phosphorylation and the
development of tauopathies. J. Biol. Chem. 274, 25490–25498. doi: 10.1074/jbc.
274.36.25490
Sontag, J.-M., Nunbhakdi-Craig, V., White, C. L. III., Halpain, S., and Sontag, E.
(2012). The protein phosphatase PP2A/Bα binds to the microtubule-associated
proteins tau and MAP2 at a motif also recognized by the kinase Fyn:
implications for tauopathies. J. Biol. Chem. 287, 14984–14993. doi: 10.1074/jbc.
M111.338681
Sotiropoulos, I., Galas,M. C., Silva, J.M., Skoulakis, E.,Wegmann, S.,Maina,M. B.,
et al. (2017). Atypical, non-standard functions of the microtubule associated
tau protein. Acta Neuropathol. Commun. 5:91. doi: 10.1186/s40478-017-
0489-6
Spillantini, M. G., and Goedert, M. (1998). Tau protein pathology in
neurodegenerative diseases. Trends Neurosci. 21, 428–433. doi: 10.1016/s0166-
2236(98)01337-x
Stern, J. L., Lessard, D. V., Ali, R., and Berger, C. L. (2017). Single-molecule
imaging of tau dynamics on the microtubule surface. Methods Cell Biol. 141,
135–154. doi: 10.1016/bs.mcb.2017.06.016
Sun, J., and Nan, G. (2017). The extracellular signal-regulated kinase 1/2 pathway
in neurological diseases: a potential therapeutic target (Review). Int. J. Mol.
Med. 39, 1338–1346. doi: 10.3892/ijmm.2017.2962
Sun, W., Qureshi, H. Y., Cafferty, P. W., Sobue, K., Agarwal-Mawal, A.,
Neufield, K. D., et al. (2002). Glycogen synthase kinase-3β is complexed
with tau protein in brain microtubules. J. Biol. Chem. 277, 11933–11940.
doi: 10.1074/jbc.M107182200
Suzuki, T., and Okumura-Noji, K. (1995). NMDA receptor subunits epsilon 1
(NR2A) and epsilon 2 (NR2B) are substrates for Fyn in the postsynaptic density
fraction isolated from the rat brain. Biochem. Biophys. Res. Commun. 216,
582–588. doi: 10.1006/bbrc.1995.2662
Tai, C., Chang, C.-W., Yu, G. Q., Lopez, I., Yu, X., Wang, X., et al. (2020).
Tau reduction prevents key features of autism in mouse models. Neuron 106,
421.e11–437.e11. doi: 10.1016/j.neuron.2020.01.038
Talbot, K., Wang, H.-Y., Kazi, H., Han, L. Y., Bakshi, K. P., Stucky, A., et al.
(2012). Demonstrated brain insulin resistance in Alzheimer’s disease patients
is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.
J. Clin. Invest. 122, 1316–1338. doi: 10.1172/JCI59903
Thurston, V. C., Zinkowski, R. P., and Binder, L. I. (1996). Tau as a nucleolar
protein in human nonneural cells in vitro and in vivo. Chromosoma 105, 20–30.
doi: 10.1007/BF02510035
Tiernan, C. T., Combs, B., Cox, K., Morfini, G., Brady, S. T., Counts, S. E.,
et al. (2016). Pseudophosphorylation of tau at S422 enhances SDS-stable dimer
formation and impairs both anterograde and retrograde fast axonal transport.
Exp. Neurol. 283, 318–329. doi: 10.1016/j.expneurol.2016.06.030
Tompa, P., and Fersht, A. (2009). Structure and Function of Intrinsically Disordered
Proteins. New York, NY: CRC Press.
Tracy, T. E., and Gan, L. (2018). Tau-mediated synaptic and neuronal
dysfunction in neurodegenerative disease. Curr. Opin. Neurobiol. 51, 134–138.
doi: 10.1016/j.conb.2018.04.027
Tracy, T. E., Sohn, P. D., Minami, S. S., Wang, C., Min, S. W., Li, Y., et al. (2016).
Acetylated tau obstructs kibra-mediated signaling in synaptic plasticity and
promotes tauopathy-related memory loss. Neuron 90, 245–260. doi: 10.1016/j.
neuron.2016.03.005
Trushina, N. I., Bakota, L., Mulkidjanian, A. Y., and Brandt, R. (2019). The
evolution of tau phosphorylation and interactions. Front. Aging Neurosci.
11:256. doi: 10.3389/fnagi.2019.00256
Umemori, H., Wanaka, A., Kato, H., Takeuchi, M., Tohyama, M., and
Yamamoto, T. (1992). Specific expressions of Fyn and Lyn, lymphocyte antigen
receptor-associated tyrosine kinases, in the central nervous system.Mol. Brain
Res. 16, 303–310. doi: 10.1016/0169-328x(92)90239-8
Uversky, V. N. (2015). Intrinsically disordered proteins and their (disordered)
proteomes in neurodegenerative disorders. Front. Aging Neurosci. 7:18.
doi: 10.3389/fnagi.2015.00018
Voskas, D., Ling, L. S., andWoodgett, J. R. (2010). Does GSK-3 provide a shortcut
for PI3K activation of Wnt signalling? F1000 Biol. Rep. 2:82. doi: 10.3410/
B2-82
Warmus, B. A., Sekar, D. R., McCutchen, E., Schellenberg, G. D., Roberts, R. C.,
McMahon, L. L., et al. (2014). Tau-mediated NMDA receptor impairment
underlies dysfunction of a selectively vulnerable network in a mouse
model of frontotemporal dementia. J. Neurosci. 34, 16482–16495.
doi: 10.1523/JNEUROSCI.3418-14.2014
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., and Kirschner, M. W. (1975). A
protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. U S A
72, 1858–1862. doi: 10.1073/pnas.72.5.1858
Weissmann, C., Reyher, H.-J., Gauthier, A., Steinhoff, H. J., Junge, W., and
Brandt, R. (2009). Microtubule binding and trapping at the tip of neurites
regulate tau motion in living neurons. Traffic 10, 1655–1668. doi: 10.1111/j.
1600-0854.2009.00977.x
White, R., Gonsior, C., Kramer-Albers, E. M., Stohr, N., Huttelmaier, S.,
and Trotter, J. (2008). Activation of oligodendroglial Fyn kinase enhances
translation of mRNAs transported in hnRNP A2-dependent RNA granules.
J. Cell Biol. 181, 579–586. doi: 10.1083/jcb.200706164
Witman, G. B., Cleveland, D.W.,Weingarten,M. D., and Kirschner,M.W. (1976).
Tubulin requires tau for growth onto microtubule initiating sites. Proc. Natl.
Acad. Sci. U S A 73, 4070–4074. doi: 10.1073/pnas.73.11.4070
Wolozin, B. L., Pruchnicki, A., Dickson, D. W., and Davies, P. (1986). A
neuronal antigen in the brains of Alzheimer patients. Science 232, 648–650.
doi: 10.1126/science.3083509
Wood, J. G., Mirra, S. S., Pollock, N. J., and Binder, L. I. (1986). Neurofibrillary
tangles of Alzheimer disease share antigenic determinants with the axonal
microtubule-associated protein tau (tau). Proc. Natl. Acad. Sci. U S A 83,
4040–4043. doi: 10.1073/pnas.83.11.4040
Xia, D., Li, C., and Götz, J. (2015). Pseudophosphorylation of Tau at distinct
epitopes or the presence of the P301L mutation targets the microtubule-
associated protein Tau to dendritic spines. Biochim. Biophys. Acta 1852,
913–924. doi: 10.1016/j.bbadis.2014.12.017
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S. M., Iwata, N., Saido, T. C.,
et al. (2007). Synapse loss and microglial activation precede tangles in a P301S
tauopathy mouse model. Neuron 53, 337–351. doi: 10.1016/j.neuron.2007.
01.010
Zhao, X., Kotilinek, L. A., Smith, B., Hlynialuk, C., Zahs, K., Ramsden, M., et al.
(2016). Caspase-2 cleavage of tau reversibly impairs memory. Nat. Med. 22,
1268–1276. doi: 10.1038/nm.4199
Zhong, H., Sia, G.-M., Sato, T. R., Gray, N. W., Mao, T., Khuchua, Z., et al.
(2009). Subcellular dynamics of type II PKA in neurons. Neuron 62, 363–374.
doi: 10.1016/j.neuron.2009.03.013
Zhou, L., McInnes, J., Wierda, K., Holt, M., Herrmann, A. G., Jackson, R. J., et al.
(2017). Tau association with synaptic vesicles causes presynaptic dysfunction.
Nat. Commun. 8:15295. doi: 10.1038/ncomms15295
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021Mueller, Combs, Alhadidy, Brady,Morfini and Kanaan. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Molecular Neuroscience | www.frontiersin.org 14 March 2021 | Volume 14 | Article 647054
